{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+saline+solution&page=29",
    "query": {
      "intervention": "Normal saline solution",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 2689,
    "total_pages": 269,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+saline+solution&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+saline+solution&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T21:05:42.264Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04977479",
      "title": "The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Allergic Reaction"
      ],
      "interventions": [
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine, Bivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "16 Years to 69 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-09-08",
      "completion_date": "2023-02-22",
      "has_results": true,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04977479"
    },
    {
      "nct_id": "NCT05456490",
      "title": "Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Liposomal Bupivacaine 13.3",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2023-04-18",
      "completion_date": "2025-02-27",
      "has_results": false,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05456490"
    },
    {
      "nct_id": "NCT00439140",
      "title": "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "botulinum toxin Type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 41,
      "start_date": "2007-06",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-01-24",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439140"
    },
    {
      "nct_id": "NCT00263562",
      "title": "Steroid Treatment for Sickle Cell Pain Crisis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Vaso-occlusive Crisis"
      ],
      "interventions": [
        {
          "name": "Steroid arm",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2005-12-01",
      "completion_date": "2008-06-13",
      "has_results": true,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00263562"
    },
    {
      "nct_id": "NCT05885035",
      "title": "Effects of Calcium Hydroxylapatite on Cellulite Dimples in the Buttocks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cellulite"
      ],
      "interventions": [
        {
          "name": "Calcium Hydroxyapatite",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kalpna Kay Durairaj, MD, FACS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 50 Years · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2023-01-01",
      "completion_date": "2023-06-26",
      "has_results": false,
      "last_update_posted_date": "2023-07-17",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05885035"
    },
    {
      "nct_id": "NCT07619885",
      "title": "The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Coronary Syndromes (ACS)",
        "Recent Myocardial Infarction",
        "Recent Stroke",
        "Peripheral Arterial Disease"
      ],
      "interventions": [
        {
          "name": "CG-0255 Besylate for Injection",
          "type": "DRUG"
        },
        {
          "name": "CG-0255 Besylate Capsule",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai CureGene Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 136,
      "start_date": "2026-06",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07619885"
    },
    {
      "nct_id": "NCT04495868",
      "title": "Bacteriostatic Normal Saline Versus Lidocaine for Intradermal Anesthesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Bacteriostatic Normal Saline",
          "type": "DRUG"
        },
        {
          "name": "1% Lidocaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-01-08",
      "completion_date": "2022-04-06",
      "has_results": true,
      "last_update_posted_date": "2023-04-18",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04495868"
    },
    {
      "nct_id": "NCT01868997",
      "title": "Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Associated Ophthalmopathies",
        "Thyroid-Associated Ophthalmopathy"
      ],
      "interventions": [
        {
          "name": "teprotumumab",
          "type": "DRUG"
        },
        {
          "name": "normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 88,
      "start_date": "2013-07",
      "completion_date": "2017-02-22",
      "has_results": true,
      "last_update_posted_date": "2024-12-17",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868997"
    },
    {
      "nct_id": "NCT01731782",
      "title": "Evaluation of a TAP Block Given During Laparoscopic Colorectal Surgery to Help Control Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Disease"
      ],
      "interventions": [
        {
          "name": "bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "normal saline placebo (for bupivacaine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2012-07",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2022-11-03",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01731782"
    },
    {
      "nct_id": "NCT01821859",
      "title": "Abraxane/Bevacizumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Abraxane",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2010-01",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2013-07-26",
      "last_synced_at": "2026-10-24T21:05:42.264Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01821859"
    }
  ]
}